Triazolam
Halcion, Triazolam (triazolam) is a small molecule pharmaceutical. Triazolam was first approved as Halcion on 1982-11-15. It is used to treat sleep initiation and maintenance disorders in the USA. The pharmaceutical is active against gamma-aminobutyric acid receptor subunit alpha-2, gamma-aminobutyric acid receptor subunit alpha-5, gamma-aminobutyric acid receptor subunit alpha-3, and gamma-aminobutyric acid receptor subunit alpha-1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
| mental disorders | D001523 |
Trade Name
FDA
EMA
Halcion, Triazolam (discontinued: Halcion, Triazolam)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| triazolam | NDA authorized generic | 2026-07-10 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| sleep initiation and maintenance disorders | — | D007319 | F51.01 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
17 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | — | 1 | — | 1 |
| Retinal detachment | D012163 | EFO_0005773 | H33.2 | — | — | — | 1 | — | 1 |
| Vitreous detachment | D020255 | EFO_1001238 | H43.81 | — | — | — | 1 | — | 1 |
| Vitrectomy | D014821 | — | — | — | — | — | 1 | — | 1 |
| Vitreous hemorrhage | D014823 | EFO_0008626 | H43.1 | — | — | — | 1 | — | 1 |
| Lens subluxation | D007906 | — | H27.1 | — | — | — | 1 | — | 1 |
| Epiretinal membrane | D019773 | — | — | — | — | — | 1 | — | 1 |
| Retinal perforations | D012167 | EFO_1001028 | — | — | — | — | 1 | — | 1 |
| Dissociative disorders | D004213 | — | F44.1 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 5 | — | 1 | — | 1 | 7 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | — | 1 | — | 1 | 2 |
| Dementia | D003704 | EFO_0003862 | F03 | — | — | 1 | — | — | 1 |
| Psychophysiologic disorders | D011602 | — | F45.9 | — | — | 1 | — | — | 1 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | 1 | — | — | 1 |
| Depression | D003863 | — | F33.9 | — | — | 1 | — | — | 1 |
| Somatoform disorders | D013001 | — | F45 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Anxiety | D001007 | EFO_0005230 | F41.1 | — | 1 | — | — | 1 | 2 |
| Dental anxiety | D016854 | — | — | 1 | 1 | — | — | 1 | 2 |
| Pain | D010146 | EFO_0003843 | R52 | — | 1 | — | — | — | 1 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | — | 1 | — | — | — | 1 |
| Cocaine-related disorders | D019970 | — | F14 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Triazolam |
| INN | triazolam |
| Description | Triazolam is a triazolobenzodiazepine. It has a role as a sedative. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1Cl)=NC2 |
Identifiers
| PDB | — |
| CAS-ID | 28911-01-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL646 |
| ChEBI ID | 9674 |
| PubChem CID | 5556 |
| DrugBank | DB00897 |
| UNII ID | 1HM943223R (ChemIDplus, GSRS) |
Target
Agency Approved
GABRA2
GABRA2
GABRA5
GABRA5
GABRA3
GABRA3
GABRA1
GABRA1
Organism
Homo sapiens
Gene name
GABRA2
Gene synonyms
NCBI Gene ID
Protein name
gamma-aminobutyric acid receptor subunit alpha-2
Protein synonyms
GABA(A) receptor subunit alpha-2, gamma-aminobutyric acid type A receptor alpha2 subunit
Uniprot ID
Mouse ortholog
Gabra2 (14395)
gamma-aminobutyric acid receptor subunit alpha-2 (P26048)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Triazolam
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,389 documents
View more details
Safety
Black-box Warning
Black-box warning for: Triazolam
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,421 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use